The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the active (transcriptionally expressed) lung microbiota of COVID-19 patients using metatranscriptomic data from bronchoalveolar lavage fluid (BALF). The researchers analyzed bacterial microbiota and virome composition to determine whether SARS-CoV-2 infection alters the lung microbial landscape. They assessed alpha-diversity, beta-diversity, and species composition to characterize dysbiosis associated with infection.
Who was studied?
The analysis drew on BALF metatranscriptomic data from 19 COVID-19 patients and 23 healthy controls. These samples came from 6 independent projects, indicating a pooled, multi-cohort secondary analysis of existing sequencing data rather than a newly recruited single-site cohort. No further demographic details are given in the abstract.
What were the most important findings?
SARS-CoV-2 infection substantially altered lung microbiota, as shown by shifts in alpha-diversity, beta-diversity, and species composition between groups. The COVID-19 group showed enrichment of pathogens such as Klebsiella oxytoca, immunomodulatory probiotics including lactic acid bacteria and Faecalibacterium prausnitzii (a butyrate producer), and Tobacco mosaic virus (TMV), together indicating severe microbiota dysbiosis. A significant correlation among Rothia mucilaginosa, TMV, and SARS-CoV-2 pointed to intense inflammatory interactions among host, virus, and other microbes in the lungs.
What are the greatest implications of this study?
The findings suggest that COVID-19 involves not just SARS-CoV-2 alone but a broader disruption of the active lung microbial community, including bacteria and viruses beyond the primary pathogen. The unexpected enrichment of the butyrate producer Faecalibacterium prausnitzii alongside pathogens highlights that dysbiosis in this context is complex rather than a simple loss of beneficial microbes. Tracking active microbiota and virome members like TMV and Rothia mucilaginosa may help explain inflammatory complications of COVID-19 and could inform future study of lung microbial contributions to disease severity.